Trial · NCT01422772
Adverse events171
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 171
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Supraventricular extrasystoles | Cardiac disorders | Group 1 - VM202 - 0.5 mg/ 1mL | 3 | 3 | 4 |
| other | Supraventricular extrasystoles | Cardiac disorders | Group 2 - VM202 - 1.0 mg/2 mL | 1 | 3 | 1 |
| other | Supraventricular extrasystoles | Cardiac disorders | Group 3 - VM202 - 2 mg/4 mL | 2 | 3 | 5 |
| other | Atrial fibrillation | Cardiac disorders | Group 1 - VM202 - 0.5 mg/ 1mL | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Group 2 - VM202 - 1.0 mg/2 mL | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Group 3 - VM202 - 2 mg/4 mL | 3 | 3 | 5 |
| other | Sinus tachycardia | Cardiac disorders | Group 1 - VM202 - 0.5 mg/ 1mL | 1 | 3 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Group 2 - VM202 - 1.0 mg/2 mL | 1 | 3 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Group 3 - VM202 - 2 mg/4 mL | 1 | 3 | 1 |
| other | Supraventricular tachycardia | Cardiac disorders | Group 1 - VM202 - 0.5 mg/ 1mL | 1 | 3 | 1 |
| other | Supraventricular tachycardia | Cardiac disorders | Group 2 - VM202 - 1.0 mg/2 mL | 0 | 3 | 0 |
| other | Supraventricular tachycardia | Cardiac disorders | Group 3 - VM202 - 2 mg/4 mL | 0 | 3 | 0 |
| other | Ventricular extrasystoles | Cardiac disorders | Group 1 - VM202 - 0.5 mg/ 1mL | 0 | 3 | 0 |
| other | Ventricular extrasystoles | Cardiac disorders | Group 2 - VM202 - 1.0 mg/2 mL | 1 | 3 | 1 |
| other | Ventricular extrasystoles | Cardiac disorders | Group 3 - VM202 - 2 mg/4 mL | 0 | 3 | 0 |
| other | Extrasystoles | Cardiac disorders | Group 1 - VM202 - 0.5 mg/ 1mL | 0 | 3 | 0 |
| other | Extrasystoles | Cardiac disorders | Group 2 - VM202 - 1.0 mg/2 mL | 1 | 3 | 1 |
| other | Extrasystoles | Cardiac disorders | Group 3 - VM202 - 2 mg/4 mL | 0 | 3 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Group 1 - VM202 - 0.5 mg/ 1mL | 0 | 3 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Group 2 - VM202 - 1.0 mg/2 mL | 0 | 3 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01422772/events